Search results
Found 41211 matches for
Today, the University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%. The new study published in the Lancet is the first peer-reviewed publication of phase 3 data from studies of a vaccine against the coronavirus.
Peter Horby
FRS Peter Horby - Moh Family Foundation Professor of Emerging Infections and Global Health
